Literature DB >> 12142499

Antiangiogenic therapy and p53.

Ester M Hammond1, Amato J Giaccia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12142499     DOI： 10.1126/science.297.5581.471a

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  2 in total

1.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

2.  Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.

Authors:  Tong Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.